Catalog No.
FHA30311
Species reactivity
Human
Host species
Human
Isotype
IgG2, kappa
Clonality
Monoclonal
Conjugation
FITC
Target
ODF, TNF-related activation-induced cytokine, Osteoclast differentiation factor, TNFSF11, TRANCE, Osteoprotegerin ligand, RANKL, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa-B ligand, CD254, OPGL
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
O14788
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
SAA0080
Target tolerance improvement of the immunogenicity assay developed for analysing samples from clinical trials of RGB-14, a proposed biosimilar to Prolia/Xgeva., PMID:40368321
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial., PMID:40350430
Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies., PMID:40220951
Visualization and quantification of RANK-RANKL binding for application to disease investigations and drug discovery., PMID:40147673
Alterations of bone proteins in medication-related osteonecrosis of the jaw., PMID:39972547
RANK/RANKL Signaling Pathway in Breast Development and Cancer., PMID:39821032
Establishing patient-derived tumor organoids of bone metastasis from lung adenocarcinoma reveals the transcriptomic changes underlying denosumab treatment., PMID:39739069
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study., PMID:39700054
Are the Soluble Receptors sRAGE, sRANKL, and Osteoprotegerin Associated with Anemia in Rheumatoid Arthritis?, PMID:39684440
In silicon desinging of RANKL-targeting vaccine for protection of osteoporosis based on the epitope of Denosumab., PMID:39580862
The Notch1 signaling pathway directly modulates the human RANKL-induced osteoclastogenesis., PMID:38040752
Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals., PMID:37373436
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial., PMID:36892190
Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption., PMID:36543965
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial., PMID:36535121
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma., PMID:36104102
Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA): A multicenter RA ultrasound prospective cohort in Japan., PMID:34260539
Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL., PMID:34112702
RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway., PMID:34108600
Management of Myeloma Bone Lesions., PMID:33806209
Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta-analysis of randomized controlled trials., PMID:33793076
ETS1 polymorphism rs73013527 in relation to serum RANKL levels among patients with RA., PMID:33592912
The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer., PMID:33119864
Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw., PMID:33065485
Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index., PMID:32955874
Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy., PMID:32826531
Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction., PMID:32732353
Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone., PMID:32539628
TNF Receptor: Fc Fusion Protein Downregulates RANKL/OPG Ratio by Inhibiting CXCL16/CXCR6 in Active Ankylosing Spondylitis., PMID:32116188
Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer., PMID:31992773
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)., PMID:31856909
Histone H3.3 mutation in giant cell tumor of bone: an update in pathology., PMID:31748824
LOX-1 is involved in TLR2 induced RANKL regulation in peri-implantitis., PMID:31655342
HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia., PMID:31578308
Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?, PMID:31268745
Excess of second tumors in denosumab-treated patients: a metabolic hypothesis., PMID:31237145
Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors., PMID:31189751
Neoadjuvant and Adjuvant Treatment with Denosumab in Aggressive Giant-cell Tumor of Bone in the Proximal Fibula: a Case Report., PMID:31188771
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases., PMID:31187176
CD21-/low B cells associate with joint damage in rheumatoid arthritis patients., PMID:31141193
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass., PMID:31120440
Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration., PMID:31101043
Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis., PMID:31075265
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial., PMID:31036625
Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases., PMID:31001277
Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern., PMID:30998511
The RANKL-RANK Axis: A Bone to Thymus Round Trip., PMID:30984193
Effector memory regulatory T cells were most effective at suppressing RANKL but their frequency was downregulated in tibial fracture patients with delayed union., PMID:30946855
Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden., PMID:30496606
Dynamics of Bone Cell Interactions and Differential Responses to PTH and Antibody-Based Therapies., PMID:30460589
For research use only. Not for human or drug use.
